Hospital Infection Therapeutics Market to Grow with a CAGR of 5.25% through 2029

Increasing incidence of hospital-acquired infections and growing healthcare expenditure and infrastructure development are factors driving the Global Hospital Infection Therapeutics Market in the forecast period 2025-2029.

According to TechSci Research report, “Hospital Infection Therapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Hospital Infection Therapeutics Market stood at USD 7.11 Billion in 2023 and is anticipated to grow with a CAGR of 5.25% through 2029. Hospital-acquired infections (HAIs), also known as healthcare-associated infections, are a major obstacle to patient safety and healthcare systems worldwide. Their prevalence is increasing, heightening the demand for effective treatments.

The primary catalyst behind the expansion of the global market for hospital infection therapeutics is the rising occurrence of HAIs. Despite advancements in infection control, HAIs persist as a significant issue in healthcare settings globally. Factors such as extended hospital stays, invasive medical procedures, antibiotic resistance, and compromised patient immune systems contribute to the prevalence of HAIs, thus fueling the need for therapeutic solutions.

Antimicrobial resistance (AMR) poses a critical global health challenge, profoundly affecting the efficacy of infection treatments and facilitating the spread of HAIs. Increased awareness among healthcare professionals, policymakers, and the public about the repercussions of AMR has spurred a greater focus on developing new therapeutics for HAIs. The imperative to tackle AMR is stimulating investments in research and development aimed at discovering novel antimicrobial agents and alternative treatment approaches.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Hospital Infection Therapeutics Market”

The Global Hospital Infection Therapeutics Market is segmented into drug type, application, region and company.

Based on application, the gastrointestinal disorders segment has emerged as the fastest growing in Global Hospital Infection Therapeutics Market. Gastrointestinal disorders often involve infections caused by pathogens such as Clostridium difficile (C. difficile) and other bacteria. Hospital-acquired infections (HAIs) are particularly common in patients with gastrointestinal issues due to compromised immune systems or extended hospital stays, leading to a higher demand for infection therapeutics specific to these conditions. The rise of antibiotic-resistant strains of bacteria affecting the gastrointestinal tract has made conventional treatments less effective. This necessitates the development of new and more effective therapeutics tailored to combat these specific infections. There has been an increased awareness and improved diagnostic techniques for gastrointestinal infections in hospital settings. This heightened awareness results in more accurate and timely diagnosis, leading to a greater demand for appropriate therapeutics. Advances in medical research and technology have led to the development of novel treatment options targeting specific pathogens responsible for gastrointestinal infections. This includes the use of targeted antimicrobials and probiotics, which are increasingly being integrated into treatment protocols. Regulatory changes and market dynamics can also play a role. For instance, shifts in healthcare policies or reimbursement structures that incentivize the development and adoption of therapies for gastrointestinal infections can drive growth in this segment.

Asia Pacific emerged as the fastest growing region in the Global Hospital Infection Therapeutics Market in 2023. The Asia Pacific region has seen a rise in hospital-acquired infections due to factors such as increasing hospitalization rates, surgical procedures, and antimicrobial resistance. This trend has heightened the need for effective infection therapeutics. There has been a growing awareness among healthcare professionals and governments in the region about the impact of hospital-acquired infections. This has prompted initiatives and policies aimed at reducing HAIs, including the use of appropriate infection therapeutics. The Asia Pacific region has witnessed significant expansion and modernization of healthcare facilities, particularly in developing economies. This expansion has led to increased demand for infection therapeutics to maintain hygiene and prevent infections. Improved access to advanced healthcare technologies and treatments has contributed to the increased diagnosis and treatment of hospital infections in the region, driving the demand for appropriate therapeutics. Pharmaceutical companies and healthcare providers have been expanding their presence in the Asia Pacific region, leading to increased availability and distribution of hospital infection therapeutics. Additionally, investments in research and development specific to the region have supported market growth.

Major companies operating in Global Hospital Infection Therapeutics Market are:

·         Merck & Co., Inc.

·         Pfizer Inc.

·         Bayer AG

·         GlaxoSmithKline Plc.

·         Daiichi Sankyo Company, Limited

·         AbbVie Inc.

·         Abbott Laboratories

·         F. Hoffmann-La Roche Ltd

·         Allergan Plc.

·         AstraZeneca Plc.

Download Free Sample Report

Customers can also request 10% free customization in this report

“The global hospital infection therapeutics market is driven by various factors, including the increasing incidence of hospital-acquired infections, rising awareness about antimicrobial resistance, technological advancements in infection control, growing healthcare expenditure, and regulatory initiatives. As the burden of HAIs continues to grow, stakeholders across the healthcare sector must collaborate to address this critical public health issue effectively. By leveraging innovative therapies, advanced technologies, and regulatory support, the industry can make significant strides in combating hospital-acquired infections and improving patient outcomes worldwide”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Hospital Infection Therapeutics Market By Drug Type (Antibiotics Drugs, Antifungal Drugs, Antiviral Drugs, Others), By Application (Bloodstream Infections, Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Disorders, Other Hospital Infections), By Region and Competition Forecast & Opportunities, 2019-2029F”, has evaluated the future growth potential of Global Hospital Infection Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Hospital Infection Therapeutics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com